Presentation of Five Research Reports Involving Daxor's Blood Volume Analyzer at the 39th Annual Society of Critical Care Medicine Conference. Part 2: Direct Blood Volume Measurement Correlated With Improved Survival

NEW YORK, NY--(Marketwire - February 4, 2010) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that five research reports were presented at the annual Society of Critical Care Medicine (SCCM) conference in Miami, FL which involved the Daxor Blood Volume Analyzer (BVA-100). The BVA-100 enables measurement of whole blood volume, including plasma volume and red blood cell volume. The Principal Investigators for these studies were Mihae Yu, MD, and Danny Takanishi Jr., MD, from the University of Hawaii, The Queen's Medical Center. Abstracts which describe their findings were published in the December 2009 Supplement (Volume 37, Number 12) of the Critical Care Medicine journal. These presentations are now available on Daxor's website at www.daxor.com/sccm2010.asp.

Three of these studies focused on whether several commonly used surrogate measures of blood volume status are in fact accurate predictors of blood volume. One of the studies, entitled "A Prospective Randomized Trial Using Blood Volume Analysis vs. Pulmonary Artery Catheter (PAC) Measurements to Guide Fluid and Red Cell Management," examined whether using blood volume data in addition to PAC data to guide resuscitation led to improved outcomes. 100 critically ill surgical patients were randomized into either of two treatment arms: resuscitation decisions in the blood volume group were based on both the blood volume as well as the PAC findings. In contrast, resuscitation decisions in the control group were based on PAC measurements alone. The results showed that use of blood volume measurement, in addition to PAC monitoring, allowed more precise quantitation of patients' needs for fluids and red blood cells. This ultimately resulted in a significant improvement in mortality in patients for whom therapy was guided by both blood volume analysis and PAC (8% mortality) vs. PAC alone (24% mortality).

Another study, entitled "A Comparison of Pulse Pressure and Blood Volume Measurement," examined whether there was a correlation between pulse pressure -- a surrogate marker of cardiac fluid responsiveness to fluid infusion -- and intravascular blood volume. Simultaneous measurement of pulse pressure and blood volume in 100 critically ill surgical patients showed that there is no relationship between these two variables.

The third study, entitled "The Relationship Between Inferior Vena Cava (IVC) Collapsibility Ratio and Measured Whole Blood Volume in Surgical Critical Care Patients," examined the correlation between IVC and blood volume. Collapsibility of the IVC is calculated as the difference between the maximum and minimum diameters of the IVC throughout the respiratory cycle. IVC is sometimes used as an estimate of central venous pressure -- which is an imperfect correlate for blood volume -- in critically ill patients. However, retrospective examination of data collected from 43 surgical critical care patients showed no relationship between IVC and blood volume.

These studies are extremely important as they demonstrate that three commonly used markers for critical care patient resuscitation status (Pulse pressure, IVC and PAC) do not provide accurate estimates of patients' blood volumes. Blood volume data is an extremely important factor in optimizing resuscitation of critically ill patients, and this information can be accurately obtained only by direct measurement of intravascular blood volume. Physicians who continue to rely on imprecise surrogate measures of volume status may under- or overtransfuse their patients with fluids and red blood cells, thereby doing harm to the patients they are trying to help. A fundamental goal of Daxor Corporation is to make direct blood volume measurement the standard of care in the treatment of critically ill patients in the intensive care unit.

The following investigators were involved in these studies: Mihae Yu, MD, Danny Takanishi, Jr., MD, Shirley Domingo, MD, Marc Osborne, MD, Sharon Moran, MD, Kevin Pei, MD, Kurt Edwards, MD, Sharon Takiguchi, MD, Susan Steinemann, MD, Maimona Ghows, MD, Andrew Tan, MD, and Fedor Lurie, MD. Further details about this research are available on Daxor's website.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information: Contact Information: Dr. Sandra Gilbert Clinical Research Coordinator 212-330-8532 sgilbert@daxor.com Stephen Feldschuh Chief Operating Officer 212-330-8500 stephen@daxor.com Diane Meegan Investor Relations 212-330-8512 dmeegan@daxor.com